Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

ConclusionsThis study confirms limited value of bevacizumab in recurrent glioblastoma independent ofMGMT status. Alkylating agents have activity in recurrent glioblastoma, especially in the context ofMGMT promoter methylation.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research